Nicox S.A. (EPA:ALCOX)

Market Cap	15.68M
Revenue (ttm)	8.43M
Net Income (ttm)	-22.39M
Shares Out	69.10M
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	139,663
Average Volume	113,234
Open	0.2468
Previous Close	0.2197
Day's Range	0.2255 - 0.2468
52-Week Range	0.1400 - 0.3840
Beta	0.88
RSI	41.68
Earnings Date	Apr 22, 2025

About Nicox

Nicox S.A., together with its subsidiaries, operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. The company’s lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. It also develops NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 28
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALCOX

Financial Performance

In 2024, Nicox's revenue was 8.43 million, an increase of 18.31% compared to the previous year's 7.13 million. Losses were -22.39 million, 7.23% more than in 2023.